Skip to main content
. 2022 Apr 28;13:893137. doi: 10.3389/fimmu.2022.893137

Figure 4.

Figure 4

PET/CT of r/r cHL patients prior to the initiation of anti-PD-1 treatment. Patient 1 presented with conglomerate lymph node masses at the anterosuperior mediastinum with the size of 37x21 mm, SUV 6.4 and the paragastric conglomerate with the size of 45x42 mm, SUV 7.4. Patient 2 presented with cervical lymph nodes with the size of 6.6mm, SUV 4.7 and with conglomerate lymph node mass at the anterosuperior mediastinum with the size of 74x42 mm, SUV 7.7. Patient 3 presented with conglomerate lymph node mass at the anterosuperior mediastinum with the size of 43x32 mm, SUV 8.2. SUV, standardized uptake value.